Marketing authorisations and decision making at the National Agency for Medicines in Finland by Tokola, Olavi
L Ä Ä K E I N F O R M A A T I O T A  L Ä Ä K E L A I T O K S E L T A
LÄKEMEDELSINFORMATION FRÅN LÄKEMEDELSVERKET, FINLAND  |  DRUG INFORMATION FROM THE NATIONAL AGENCY FOR MEDICINES, FINLAND 
1 . 2 0 0 4
Politiikasta toimin-
taan 3 Kuukautishäi-
riöiden hoito 4 Myyn-
tilupa-asioiden käsit-
tely ja päätöksen te-
ko 7 Lääkevalmistei-
den määräämiseen tai
toimittamiseen liitty-
vistä ehdoista ja suo-
situksista 10 Metyy-
lifenidaattihydroklo-
ridi 12 Aprepitantti
14 Ertapeneemi 15
Silmään kohdistuneet
S a m m a n d r a g
Ledare
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Kati Ojala . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Om biverkningar
Tapani Vuola  | Leena Sommarberg  . . . . . . . . .
Om läkemedel för djur
Tita-Maria Saukko . . . . . . . . . . . . . . . . . . . . .
S u m m a r y
Editorial
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Kati Ojala . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Olavi Tokola . . . . . . . . . . . . . . . . . . . . . . . . . .
ADR News
Tapani Vuola | Leena Sommarberg  . . . . . . . . .
29
30
33
35
36
37
40
43
45
Från politik till åtgärder
Behandling av menstruationsrubbningar
Om ögonbiverkningar
Avmaskning av hundar och katter
From policy to action
Treatment of menstrual disturbances
Marketing authorisations and decision making at the
National Agency for Medicines in Finland
Adverse reactions in the eyes reported in Finland
Lääkelaitoksen päätöksiä
1.2004
12. vuosikerta
12 årgången
12th Annual volume
36 TABU 1.2004
Last autumn, the Ministry of Social Affairs and Health
published Finland’s first official Pharmaceutical Policy
document (STM 2003:11). Comparable policy agendas
have been used routinely as guidelines for quite some
time elsewhere in the social and health care sector. In a
rapidly changing world, the  pharmaceutical field can-
not be left to rely on “ad hoc” policy – intentional plan-
ning is certainly needed.
Public reaction to outlines of the Pharmaceutical 
Policy 2010 has been moderate or downright subdued.
The most likely reason for this could be that there is no
need for significant changes of principle behind the
structure of pharmaceutical services, especially since
generic substitution was implemented in April 2003.
The subject that has raised the most discussion concerns
the proposed gradual elimination of the progressive
pharmacy fee, which would enable a reduction in the re-
tail prices of medicines by about 7 percent. The Min-
istry of Social Affairs and Health has requested The Na-
tional Agency for Medicines in Finland to define the
matter by 30.11.2004.
Many other matters have failed to elicit much com-
ment. This can be interpreted as acceptance of the pro-
posals, which leads one to expect that the policy guide-
lines will be put into action. To mention a few exam-
ples:
• The measures taken by the Social Insurance Institution
and the Centre for Pharmacotherapy Development in
Finland in developing a system of prescription informa-
tion feedback in order to promote rational prescribing of
medicines.
• Promoting the Drug Utilisation Review scheme at phar-
macies.
• Increasing and promoting public awareness of correct
and safe usage of medicines, and the inclusion of  drug
information in health education at school.
• Reviewing the drug reimbursement system.
• Ensuring the equalisation of medicine prices, and the
passing any potential discounts granted by the pharma-
ceutical industry to all pharmacists and consumers.
• Reviewing the functions and activities of the  current
pharmaceutical authorities, and possibly reorganising the
work between them.
• Finland’s more active participation in collaboration at
EU level.
• Providing the operational prerequisites for pharmaceuti-
cal research.
No policy document can be all-inclusive. It has been
pointed out, and with reason, that the Pharmaceutical
Policy 2010 outlines lack developmental visions of drug
utilisation at hospitals and health centres. This omission
should be taken into consideration in future action pro-
grammes. Safe, efficient and economical  pharmaceutical
care can only be provided at hospitals, if their drug util-
isation is based on sufficient expertise and guidance all
the way from the hospital pharmacy  to the bedside of
the patient.
This year, the National Agency for Medicines will fo-
cus especially on increasing the influence and impact on
the EU, on starting the general planning of  pharmaceu-
tical services, and on advancing its Internet services. In
the supervision of medical devices, a risk management
model will be produced for health care units. These ob-
jectives have been agreed upon jointly with the Ministry
of Social Affairs and Health.
As the Ministry’s policy outlines extend until the
year 2010, there are still seven years left for various
stages of implementation. Our point of departure is
favourable. Let us reinforce our current strengths and
eliminate our perceived weaknesses.
Hannes Wahlroos
DIRECTOR GENERAL, PROFESSOR
National Agency for Medicines
From policy to action
Editorial
Summary 
Translation Sari Jay
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Until as late as the 1800s girls usual-
ly got married when they reached
puberty. In the mid 1850s, however,
puberty was reached later than at
present, it used to be at 17 years. At
the time when women got married
at the age of menarche and contra-
ception was unknown, the rhythmic
cycle of a woman’s life was main-
tained by pregnancies and by lacta-
tion, which was used as a means of
contraception, up until the age of
menopause. Consequently, a woman
in her lifetime may at best only have
had a couple of menstruations.  
The menstrual cycle
In the follicular phase, the follicle-
stimulating hormone (FSH) secreted
by the anterior pituitary gland stim-
ulates the ovaries. One of the ova is
selected to become the dominant fol-
licle and it grows bigger than the
others. The dominant follicle pro-
duces oestrogen, which is the pre-
dominant hormone during the initial
stage of the menstrual cycle. Oestro-
gen promotes proliferation of the
endometrium while the number of
small arterioles and glandular struc-
tures in the functional layer of the
endometrium is increased.
Towards the middle of the men-
strual cycle, the level of oestrogen
and the luteinising hormone (LH)
secreted by the anterior pituitary
reaches its peak. The LH peak caus-
es the ovum to become loose, i.e.
ovulation occurs. Following ovula-
tion the ovarian follicle becomes the
corpus luteum. This secretes proges-
terone for the subsequent 14 days.
The glandular activity in the
endometrium accelerates and mucus
is produced in increasing amounts.
This is the secretory phase of the
uterine endometrium. If no fertilisa-
tion occurs, the corpus luteum
begins to degenerate after 14 days.
The decrease of progesterone secre-
tion results in the start of the men-
strual discharge. The functional
endometrium is shed together with
the discharge of blood and tissue
debris. The endometrium has vari-
ous mechanisms for maintaining the
discharge: fibrinolysis comes into
effect in order to prevent the blood
from clotting and keep it flowing.
Prostaglandins also cause the uterus
to contract in order to empty it of
blood as effectively as possible. But
as soon as the discharge has started
an effective regeneration of the
endometrium begins. The duration
of the menstrual discharge depends
on the balance between, on the one
hand, the factors which maintain the
discharge and, on the other, those
that stimulate the regeneration.
Menstrual disturbances are very
common. There is probably no
woman who has not had menstrual
problems on occasion. The menstru-
al discharge may be profuse or too
scanty, too frequent or too infre-
quent; it may occur irregularly or be
absent altogether. The following is a
description of a sample patient for
each problem.
A discussion of the cause and
treatment of menstrual discharge
disorders is started by reckoning the
age of the woman. The cause of dis-
charge disorders in women at differ-
ent ages is typical of their age group.
Profuse and irregular menstrual dis-
charge is a typical problem for
young women, for instance. The
cause of the problem is nearly
always a disturbance in ovarian fol-
licle maturation, i.e. some of the
cycles are anovulatory. The same
problem with the same explanation
is also found at the other end of the
fertile age, i.e. women nearing the
menopause. In age groups in
between the two, the profuse and
irregular discharge is explained by
something other than ovulatory dis-
orders, the most likely explanation
being found in the uterus. Ignoring
hypothyroidism or hyperthyroidism
and hyperprolactinemia, systemic
diseases as an underlying cause for a
discharge problem are very rare and
in practice need not be considered.
The focus in problem solving is
on the endocrinological causes.
Profuse menstrual discharge
The cause of profuse menstrual dis-
charge may be found in the uterus:
fibromyoma, adenomyosis, a polyp
or endometrial hyperplasia, or sim-
ply an IUD (intrauterine device). On
rare occasions, the underlying prob-
lem may be a congenital prosta-
glandin imbalance or excessive fibri-
nolysis. The most common hormon-
al cause is an anovulatory cycle.
Ritva 45 years 
She has been delivered of three chil-
dren, the contraception method used
being sterilisation. Her menstrual
cycle is fairly regular, 28–30 days.
The duration of discharge has in the
past been 5–6 days, and the flow of
discharge has always been fairly
copious. During the past year, the
discharges have become even more
copious and are of longer duration.
The doctor considers the uterus to
be “clumsy”, Pap smear is of class
1, similar to the endometrial biopsy.
Treatment of menstrual disturbances
Kati Ojala
GYNAECOLOGIST, LECTURER
University of Oulu, Oulu University Hospital
Nowadays the average age of menarche is 12.5 years, and a woman will in her lifetime menstruate
350–400 times. Menstruation is a modern problem.
Summary 
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Ultrasonography of the vagina
reveals two small fibromyomata in
the uterine muscular layer.
• There are a couple of treatment
alternatives. The amount of men-
strual discharge could be decreased
by 20–30% by using anti-inflamma-
tory analgesics. The alleviation of
menstrual pain would be an addi-
tional advantage. In practice, few
women want to take regular high
doses of anti-inflammatory anal-
gesics, considered to be painkillers.
Another drug which reduces the
amount of menstrual discharge is
tranexamic acid, an inhibitor of fib-
rinolysis. Similarly to anti-inflamma-
tory analgesics, it is taken on the
days when the discharge is most
profuse. It reduces the amount of
discharge by as much as 50%. Con-
traceptive pills containing natural
oestrogen could also be used to
reduce the amount of discharge. It is
likely that this woman has been ster-
ilised because she is unwilling to
take pills. A hormonal IUD is rec-
ommended as the primary treatment
alternative in this case. The reduc-
tion of discharge is as high as 90%
in users of a hormonal IUD, and
after using it for a year 30% of the
women attain amenorrhoea.
Oligomenorrhoea is also common
during the first months of use.
• In this case, the fundamental cause
of the profuse discharge remains
incompletely explained. The
patient’s age may be the reason why
some of the cycles are anovulatory,
in which case only the oestrogen
effect is shown on the endometrium.
Oestrogen has a thickening effect on
the endometrium until the endo-
metrium atrophies due to old age.
This is contradicted by the fact that
the menstrual discharges are regular
and relatively similar time after
time. Small fibromyomata could be
another possible explanation. In this
case the efficacy of a hormonal IUD
is not 100% certain. In contemplat-
ing surgery, the options include
ablation of the endometrium and
hysterectomy.
Riina 15 years
Menarche at 12 years with a con-
stantly irregular cycle 28–45 days.
The duration of menstrual discharge
is long, even 9–10 days, and the dis-
charge is profuse. Ingestion of iron
keeps the haemoglobin level with
difficulty above 100.
• The long, irregular cycle in the
young woman is explained by
anovulatory cycles. The ovulation is
regulated by FSH and LH secreted
by the anterior pituitary; the secre-
tion is stimulated by gonadotrophins
from the hypothalamus in rapid, fre-
quent pulses. The hypothalamus
matures slowly, and the gonado-
trophin secretion is not yet taking
place in quick enough pulses in a
teenage girl. During the first year
after menarche only 15% of the
cycles are ovulatory while 85% are
anovulatory. Beginning from the
start of menarche, the hypothalamus
matures gradually during a period of
8–9 years, when it reaches the activ-
ity of that of an adult woman. The
later the menarche, the slower the
maturation.
• Appropriate treatment for the dis-
charge disorder would be the con-
traceptive pill. A trial break in the
administration of the pill could be
taken after 6–12 months to see
whether the patient’s own cycle has
become regular, i.e. whether the time
has solved the problem.
Menstrual discharge too scanty
Nina 38 years 
Three pregnancies and one delivery,
smokes 5 cigarettes a day. Contra-
ceptive methods tried consist of an
IUD and a hormonal IUD, but they
were inappropriate. Contraceptive
pills containing natural oestrogen
are used at present. The first six
months were trouble-free, even
though the amount of discharge was
reduced each time. The discharge
finally ceased altogether.
• Very few examinations are
required: pregnancy test, TSH and
prolactin. If the gynaecological sta-
tus is also normal, nothing needs to
be done. The patient can continue
taking the contraceptive pill.
Menstrual discharge too 
frequent
The cycle is short from one time of
onset until the next, i.e. 23 days,
even less than 20 days at its short-
est. These problems occur at both
ends of the fertile age.
Tiina 43 years
The cycle is short, 18–22 days. The
duration of the discharge is 5–6
days, copious amounts at times. 
Two pregnancies; sterilisation used
as the contraceptive method. TSH
and prolactin are normal.
• An ovulatory disorder is likely.
The FSH level is beginning to rise
slowly after the age of 40. Hence the
follicular phase is reinforced and the
ovarian follicle matures even more
quickly. Ovulation occurs as early as
on the 10th day, and the corpus
luteum remains weak. Appropriate
treatment consists of progestin sup-
port with a potent luteal hormone
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on the 10th–25th day of the cycle.
The other alternative is the contra-
ceptive pill.
Menstrual discharge too 
infrequent
Hanna 24 years
No pregnancies, menarche at 12
years of age with an irregular cycle
in the past. Taken the contraceptive
pill for seven years with regular
menstrual discharge at that time.
The administration of the pill had
been discontinued 8 months previ-
ously in the hope of becoming preg-
nant. Two months were trouble-free,
followed by a prolongation of the
cycle to 30–50 days. Findings at the
time: mildly overweight, weight
index 26. TSH and prolactin nor-
mal. Ultrasonography of the vagina
reveals slightly cystic looking
ovaries, does not actually fulfil the
criteria of a polycystic ovary disease.
• As the patient wishes to become
pregnant, it is recommended that
she be referred to a fertility clinic for
follow-up treatment. The patient
could try a mild, cyclic progestin,
e.g. dydrogesterone, during the
queuing time.
Irregular menstrual discharge
Eija 40 years
Two children; sterilisation used as
the contraceptive method. The cycle
regular in the past, 28–29 days,
duration of 5 days. Irregular dis-
charge for the previous four months:
“Normal discharge at first, followed
by eight days of no discharge. Dis-
charge in tiny amounts followed
thereafter, which lasted for five days.
Then ten days without discharge fol-
lowed, after which normal menstru-
al discharge appeared... etc.”  Pap
smear and endometrial biopsy are
normal. In the right ovary, ultra-
sonography reveals a cyst which is
without an internal echo, has a sin-
gle chamber, and with a diameter of
4.6 cm.
• A small amount of oestrogen is
probably secreted from the cyst,
which is enough to confuse the
endometrium. The cyst appears
benign, however, and a 5 cm cyst in
a woman of fertile age needs no
treatment. The appropriate treat-
ment would be a cyclic luteal hor-
mone on the 12th–25th day of the
cycle.
Menstrual discharge is missing
altogether
Outi 18 years
Menarche at 14 years of age with
always irregular cycle, variation of
duration 4–7 days, scanty. The men-
strual discharge gradually ceased
altogether; the last discharge having
occurred five months previously.
Status: 166 cm, 47 kg, weight index
17. Pregnancy test negative. Gynae-
cological status normal, except that
the ultrasonography of the vagina
revealed an endometrium tenuously
thin.
• Progestin testing will be carried
out as a follow-up, i.e. a luteal hor-
mone, e.g. dydrogesterone, will be
prescribed for 10 days. If menstrual
discharge continues after treatment,
no further examinations are neces-
sary. If discharge does not occur,
checking will be carried out of TSH,
prolactin and FSH. A high level of
FSH is an indication of ovarian
insufficiency, i.e. FSH is trying to
reanimate inactive ovaries. The
underlying cause of the disorder
may be an autoimmune disease;
such are, however, rare. If FHS is
normal, which is the most likely
outcome, the disorder is of the
hypothalamus. The patient’s slim-
ness is an additional factor.
A contraceptive pill is the most
appropriate treatment. A pill with
the lowest level of hormone may not
have a sufficient amount of oestro-
gen, and consequently, menstrual
discharge will still remain absent. A
pill with a higher level of oestrogen
is recommended in such a case.
Some young women, especially
those with an anorexic tendency,
would prefer to use preparations
intended for the treatment of the
menopause rather than the contra-
ceptive pill.
Conclusion
When menstrual disorders occur in a
woman, the precise problem is to be
investigated first. Thereafter the
patient’s age is to be taken into con-
sideration. Pregnancy, uterine disor-
ders and the most common endo-
crinological disorders (those of the
thyroid gland) are excluded. The
problem usually consists of either
profuse or irregular menstruation.
The most appropriate medical treat-
ment to reduce profuse menstrual
discharge is the contraceptive pill or
a hormonal IUD. A cyclic luteal hor-
mone or the contraceptive pill is
appropriate for controlling irregular
menstruation.
A consistent and resolute endeavour
towards developing the activities
and organisation of the National
Agency for Medicines in Finland has
been made in order to conform with
the EU procedures of marketing au-
thorisation, legislative reforms, and
requirements imposed by the en-
largement of the EU. Examples of
this work include the abolition of
the Management Board in the year
2000, the reorganisation of the
Committee on Safety, Efficacy and
Quality of Medicines in 2002, and
the reorganisation of the Agency in
2003, involving the increase of re-
sources at the Department for Mar-
keting Authorisations, and the relo-
cation to new premises in the au-
tumn of 2004.
The new organisation
The structure and scope of the or-
ganisation were codified at the end
of 2002, and the reorganisation was
gradually introduced last year. The
increased resources and new premis-
es are the final touches to the reor-
ganisation, in which the new spe-
cialised units with their individual
teams concentrate on marketing au-
thorisation procedures.
The new organisation in force
since 1.1.2003 is shown in Figure 1.
The reorganisation of the marketing
authorisation procedures was the
most extensive one of them all: three
units in the line organisation were
abolished and replaced by one de-
partment accountable for marketing
authorisations. The operations of
the department were designed in ac-
cordance with process organisation,
with emphasis on the strategic aims,
on the quality of the operations and
good customer service.
The Department for Marketing
Authorisations consists of four sec-
tions dealing with the authorisations
and one section dealing with process
development and support. The
strength of the Department amounts
to 62 persons. The customers are
the users and prescribers of pharma-
ceutical products, and those respon-
sible for the treatment of domesctic
animals. The medicinal products are
evaluated for their efficacy, safety,
and quality. The new process-based
organisation was established to bet-
ter respond to the direct external
client relationships, i.e., those com-
prising the marketing authorisation
applicants and holders.
The clients of sections 1 and 2
consist of innovative pharmaceutical
companies, whereas the clientele of
section 3 includes innovative veteri-
nary pharmaceutical companies and
entrepreneurs within the veterinary
and herbal medicinal product indus-
tries. Section 3 also includes a logis-
tics and filing team serving the en-
tire Department and ensuring the
correct location of the documents.
The clients of section 4 consist of
representatives of the generic phar-
maceutical industry.
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Olavi Tokola
PROFESSOR, HEAD OF DEPARTMENT
Marketing authorisation
National Agency for Medicines
Summary 
Marketing authorisations and decision making at
the National Agency for Medicines in Finland
Figure 1
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Co-operation with the interest
groups is emphasised in the opera-
tions of the Section Process Develop-
ment and Support (PDS). Clients of
all the sections also include EMEA
and the Commission.
Figure 2 shows the operations
and role of Sections with centres of
scientific advice, biotechnology, lo-
gistics and filing, and quality assess-
ment. 
Responsibilities and quality 
assurance
The Head of the Department for
Marketing Authorisations shoulders
the overall responsibility, as well as
the responsibility for the perfor-
mance and identification of the tar-
gets of the organisation. It is his task
to ensure the correct prerequisites
for work, encourages people in their
tasks and in accepting new chal-
lenges; and together with other
members of staff he also deals with
issues associated with various inter-
est groups.
The Heads of Sections are ac-
countable for the procedures of their
own sections. They ensure the prop-
er management of their sections, re-
liable deliveries, performance, quali-
ty and maintenance of expertise.
Good and correct use of resources
and proper quidance for the experts
are part of the quality aspects of
management. The Head of Process
Development and Support is the de-
velopment and quality manager of
the Department. Her responsibilities
include the quality and promotion
of procedures in the working prac-
tices of the sections and client con-
tacts. The monitoring of the market-
ing procedures in the EU, and their
implementation in Finland, as well
as the promotion of the use of IT
applications, are also part of her re-
sponsibilities. The Head of Process
Development is also in charge of
parallell import authorisations, ex-
port certificates, and exemptions
from annual fees.
The simplified flow of processing
on marketing authorisation applica-
tion is shown in Figure 3. Each
Head of Section is responsible for
the quality, consistency and verifica-
tion of evaluations before the meet-
ing at which the decision is pre-
pared. Quality assurance of the con-
tents, for example, is required espe-
cially for new medicinal substances
or significant novel indications or in
connection with a major objection
to an assessment submitted by an-
All therapy areas of generics 
Centre of quality assessment
expertise
Veterinary medicinal products 
Herbal medicinal products
Logistics and filing team
E.g.antidiabetics, drugs for car-
diovascular and nervous sys-
tem diseases, hormones,
anti-infectives
Scientific advice
E.g. lipid-lowering, anti-
neoplastic and antirheumatic
agents, drugs for respiratory
systems, vaccines, immuno-
suppressants 
Biotechnology expertise centre
The clients submit
- applications for MA
- variation applications, etc.
The clients receive
- scientific/administrative advice
- assessment reports
- queries
- hearings
- decisionsSection
4
Section
3
Section
2
Section
1
PDS
Figure 2
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other member state. A second opin-
ion, or a referee type of statement in
this instance, can be obtained from
a member of the Committee on
Safety, Efficacy and Quality of Med-
icines, or from a permanent expert
or the expert group of the Finnish
Agency.
A co-ordinated administrative
quality assurance meeting is a con-
trol point before the decision of a
marketing authorisation is made, en-
sures that overall quality measures
have been taken, the considerations
and conclusions fulfilled and docu-
mented. The meeting is chaired by
the Head of the Department for
Marketing Authorisations and the
participants include the marketing
authorisation co-ordinators, the
Head of Process Development and
Support, the Project Manager, Head
of Section 4 and the Head of Safety
and Drug Information. 
The Director General makes the
decisions on new applications for
marketing authorisations, renewal
applications in cases where the ap-
plication is presented to be rejected,
and on the variations of prescription
status. The Head of the Department
for Marketing Authorisations deter-
mines the extensions of indications,
and variations. 
The Heads of Sections decide the
renewals of marketing authorisa-
tions, variations on summaries of
product characteristics (SPCs) and
package information leaflets (PILs),
comments made by Finland in mutu-
al recognition procedures with re-
gard to new active substances, new
combinations or major objections,
and transfers of marketing authori-
sations to new holders. The Head of
Section 4 in addition makes deci-
sions regarding variations concern-
ing quality.
Improved customer service
The new organisation and new lines
of action, with their focus on clients
and procedures, result in an overall
control of issues associated with
marketing authorisations. Consisten-
cy is also achieved in the decisions
made in the various procedures for
marketing authorisations: all appli-
cations related to certain therapy
area are evaluated by one and the
same team. The multiprofessional
teams of the different sections form
an ideal base for development in the
maintenance and distribution of ex-
pertise. 
Where is the quality of work 
recognised? 
Simply in two respects: reliable de-
liveries and predictability, i.e. a good
application will have the expected
outcome. 
With genuine collaboration and
fairness the Department for Market-
ing Authorisations will become a
happy and capable working unit.
This should also be apparent in an
improved ability to cope with the
work and additionally improved
customer services for applicants and
holders of marketing authorisations.
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Drugs can cause adverse reactions in
the eyes in many ways, without the
mechanism of the adverse reaction
being always fully understood.
Drugs administered in the eyes may,
understandably, cause topical irrita-
tion and allergic reactions, but sys-
temically administered drugs may al-
so affect the eyes in many ways. In
addition to allergic reactions, ad-
verse reactions in the eyes concern
for example increased intraocular
pressure, intraocular haemorrhage
and other vascular disorders such as
thromboembolism and toxic effects
on the retina and on the optic nerve,
as well as lens opacity.
Reported adverse ocular 
reactions 
During its existence, i.e. ever since
1973, the National Agency for Med-
icines in Finland has received over
600 reports on suspected adverse oc-
ular reactions. These comprise about
3% of all reports received. 
An individual report may even
have included other adverse reac-
tions or symptoms without the ef-
fects on the eyes being necessarily
the primary effects. A single report
may contain several drugs.
Approximately 20% of all cases,
have been classified as serious. 
Eye irritation
The definitive majority of reports
have been associated with diverse
symptoms of irritation of the surface
of the eye of varying severity, such
as stinging, a sensation of a foreign
body in, or dryness of, the eye, or
increased lacrimation. Consequently,
as many as 200 adverse reactions
have been reported as conjunctivitis.
The above symptoms can have
been mainly caused by beta-block-
ers, with emphasis on the beginning
of the adverse reaction register (136
reports, 81 of which were associated
with the use of non-selective beta-
blockers). In recent years, eye symp-
toms caused by cardiovascular
agents have hardly been reported,
whereas for example 11 reports
have been made on statins with as-
sociated visual disorders. Five re-
ports in the group of statins were as-
sociated with the use of atorvastatin.
Some of the reported symptoms
of eye irritation are explained by al-
lergic reactions of varying degrees.
For example, skin rash, pruritus and
dyspnoea have been reported at the
same time. These types of reactions
occur predominantly in the group of
drugs administered in the eye (21 re-
ports). Also in six cases the use of
X-ray contrast media was found to
be associated with a distinct gener-
alised allergic reaction.
Abnormal vision
A total of 135 reports have been of
various cases of abnormal vision.
Some of these have included con-
junctivitis or other eye symptoms.
This symptom has been caused by a
varied group of drugs. The drugs
most frequently reported expectedly
include ethambutol, an anti-tubercu-
lous drug, and, in a few cases, hor-
monal contraceptives (7), rofecoxib
(4), and three reports of each of
telithromycin, cefaclor and citalo-
pram. Adverse reactions in the eye
have been referred to in the summa-
ry of product characteristics of rofe-
coxib, telithromycin and citalopram,
but not that of cefaclor.
Visual field defect
Visual field defect was the cause of a
report on 52 occasions. Nearly all of
these were associated with the use of
vigabatrin. Optic neuritis or neu-
ropathy has been mentioned in the
register 29 times. The drug most
commonly suspected is ethambutol,
and there have been some cases sus-
pected of being caused by the use of
amiodarone. Keratitis has been re-
ported on 19 occasions mainly in
the 1970s and 1980s. There are 17
reports of double vision/diplopia.
The only distinct drug in the group
is zolpidem (3 reports of diplopia),
the use of which has also been asso-
ciated with reported cases of visual
hallucinations, and, in two individ-
ual cases also accommodation or
other visual disorder. The risks of
diplopia and hallucinations are also
mentioned in the summary of prod-
uct characteristics. Keratic opacities
were reported on 9 occasions with
amiodarone as the main culprit
again (7 cases). Another suspected
drug was chlorpromazine, however,
in association with asiclovir in one
report.
Adverse reactions in the eyes reported in Finland
Tapani Vuola
SENIOR MEDICAL OFFICER
Leena Sommarberg
RESEARCHER
Safety&Drug Information
National Agency for Medicines
Summary 
ADR News
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Cataract and glaucoma
Cataract has been reported in 12
cases. In three cases the suspected
drug was the steroid. Glaucoma was
reported on 10 occasions, but no
drug was particularly predominant
in such a small group, even though
various antidepressants are used
widely, and even though warnings
are issued of this adverse effect asso-
ciated with these drugs. Isolated cas-
es associated with new antidepres-
sants have been reported in the liter-
ature. 
Blindness and colour blindness
The most serious adverse reaction
occurring in the eye is blindness,
which has been reported 5 times. In
two of the cases the reported drug
was quinine, one of the known ad-
verse reactions of which is, in fact,
blindness. Consequently, a prepara-
tion containing quinine was in 2002
withdrawn from over-the-counter
status. One of the cases of blindness
occurred during thrombolytic treat-
ment as a result of ocular haemor-
rhage, one case included the use of
ethambutol (see below) and one in-
cluded practolol, the use of which
was associated with conjunctivitis
and followed by severe keratitis.
Colour blindness was reported
on four occasions, again with
ethambutol being the main culprit in
all the cases. Colour blindness is of-
ten one of the first symptoms of
ophthalmic nerve damage. Harmless
and temporary change of colour vi-
sion probably caused by sildenafil
was only reported once.
Drugs with a potentially harmful
effect on the eye
Beta-blockers have been discussed
above, their biggest harmful effect
being dryness of, and sensations of
irritation in, the eye. After this
group, the second largest group with
associated suspected adverse reac-
tions is the anti-mycobacterials with
42 reported cases. Thirty-seven of
them involved ethambutol, which
has also been suspected of having
caused various types of damage to
the optic nerve, such as optic nerve
inflammation, retrobulbar neuritis,
optic atrophy, colour blindness and
blindness once. In some cases only
visual disorders in general have been
reported. Other anti-tuberculous
drugs are not to be found more of-
ten than in a few isolated cases.
Adverse reactions on the eye as-
sociated with the antiarrhythmic
amiodarone have been reported on
nine occasions, the majority of
which involved keratinic deposits,
but also three cases of keratitis and
one case of keratic opacity. Corneal
changes are a result of accumulation
of amiodarone on the cornea. Dam-
age to the optic nerve has been re-
ported 3 times. In the summary of
product characteristics full examina-
tion of the eyes is advised in case
obscuration of the vision or visual
impairment occurs.
Various quinine derivatives are
known for their potentially harmful
effects on the eye. Three cases of
blindness from the use of quinine
combination were reported in the
1980s. One of these, however, was
reported as having been temporary.
Chloroquin, an anti-malarial drug in
Finland, has been reported 5 times,
three of which reports involved ker-
atic opacity, one a suspected case in-
volving precipitation and one macu-
lar degeneration. No adverse effects
on the eye have been reported with
the use of mefloquine.
Adverse reactions with effects on
the eyes caused by vigabatrin have
also been reported in Finland, about
fifty times. Except in a couple of
cases: its best known adverse reac-
tions involves certain types of visual
field defect.
Conclusion
In the Finnish ADR register, adverse
reactions on the eyes form about
3% of all the reports. The majority
of them are harmless symptoms of
irritation of the surface layers of the
eye or temporary visual distur-
bances. Some drugs may neverthe-
less harm the optic nerve and even
cause permanent blindness. Even
though permanent adverse reactions
on the eyes are rare, their potentiali-
ty should be borne in mind in the
use of drugs.
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